8-K: Clene Advances ALS and MS Programs with Positive FDA Feedback and Key Meetings Scheduled

Clene Inc. announced constructive feedback from the FDA on its neurofilament biomarker analysis plan for ALS and confirmed two additional FDA meetings in Q3 2025, keeping its ALS NDA submission on track for late 2025.

Summary

• Clene Inc. received constructive feedback from the U.S. Food and Drug Administration (FDA) during a Type C meeting regarding its proposed statistical analysis plan (SAP) for neurofilament light (NfL) biomarker data from its NIH-sponsored Expanded Access Protocol (EAP) for ALS.
• The FDA provided supportive feedback on the analysis methodology for assessing NfL change, which will be analyzed after 9 months (primary) and 6 months (supportive) of CNM-Au8 treatment.
• The Agency's acceptance of the revised SAP, incorporating FDA's requested revisions, is expected in summer 2025, establishing an agreed-upon framework for NfL change analyses.
• NfL analyses are scheduled to be conducted early in the 4th quarter of 2025.
• If NfL findings demonstrate a clinically meaningful decline, they may support a New Drug Application (NDA) submission under the accelerated approval pathway, planned for the end of 2025.
• Two additional FDA meetings are confirmed for the 3rd quarter of 2025: an ALS Survival Data Type C Meeting to review long-term survival benefit from CNM-Au8 30 mg treatment for potential NDA filing, and an End-of-Phase 2 Type B MS Program Meeting to discuss VISIONARY-MS trial results and the planned Phase 3 study focusing on cognition improvement in MS.
• CNM-Au8 is an investigational first-in-class therapy designed to improve central nervous system cell survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.

Sentiment

Score: 8

Explanation: The document conveys strong positive sentiment due to constructive FDA feedback, acceptance of a key analysis plan, and the scheduling of two additional critical FDA meetings, all indicating significant progress towards potential drug approvals for major neurodegenerative diseases.

Positives

• FDA provided constructive and supportive feedback on the proposed neurofilament biomarker analysis plan for ALS.
• The Agency's acceptance of the revised statistical analysis plan (SAP) is expected in summer 2025, providing a clear framework for future analyses.
• The New Drug Application (NDA) submission for ALS under the accelerated approval pathway remains on track for potential submission by the end of 2025.
• Two additional crucial FDA meetings are scheduled for Q3 2025, covering long-term ALS survival data and the End-of-Phase 2 results for the MS program, indicating active regulatory progress across key indications.

Risks

• General market conditions could impact company performance.
• Clinical trials may not demonstrate the efficacy and safety of drug candidates to the satisfaction of regulatory authorities, or may not produce positive results, potentially leading to additional costs or delays.
• Clinical results for drug candidates may not support further development or marketing approval.
• Actions of regulatory agencies may affect the initiation, timing, and progress of clinical trials and marketing approval.
• Ability to achieve commercial success for drug candidates, if approved, is not guaranteed.
• Limited operating history and ability to obtain additional funding for operations and to complete development and commercialization of drug candidates are ongoing concerns.

Future Outlook

Clene is advancing its ALS and MS programs with the goal of delivering innovative therapies for neurodegenerative diseases. The company anticipates conducting NfL analyses early in Q4 2025, which, if positive, could support an NDA submission for ALS by the end of 2025. Additionally, planned FDA meetings in Q3 2025 will review long-term ALS survival data and discuss the planned Phase 3 study for MS, focusing on cognition improvement.

Management Comments

• "We are encouraged by the FDAs collaborative approach and their constructive feedback on our NfL biomarker analysis plan from the ongoing NIH-sponsored EAP program."
• "With two additional FDA meetings scheduled to discuss long-term ALS survival results and the End-of-Phase 2 MS results, we are advancing our ALS and MS programs to deliver an innovative therapy for people living with neurodegenerative diseases."

Industry Context

This announcement highlights the ongoing rigorous regulatory process for novel therapies in the neurodegenerative disease space, a field with significant unmet medical needs. Clene's focus on mitochondrial health and the NAD pathway with CNM-Au8 represents an innovative approach within the biopharmaceutical industry, aiming to address complex conditions like ALS and MS where effective treatments are limited.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the document to allow for a direct assessment against global benchmarks.

Stakeholder Impact

• Shareholders: Positive impact due to significant regulatory progress for key drug candidates, potentially increasing the likelihood of future market approvals and commercialization.
• Patients (ALS and MS): Potential for new, innovative therapies to address critical unmet medical needs, offering hope for improved outcomes.
• Employees: Continued progress in clinical development and regulatory affairs provides stability and validates ongoing research and development efforts.

Next Steps

• FDA's acceptance of the revised statistical analysis plan (SAP) for NfL biomarker analysis (expected Summer 2025).
• Conducting NfL biomarker analyses (early 4th Quarter of 2025).
• ALS Survival Data Type C Meeting with FDA (3rd Quarter of 2025).
• End-of-Phase 2 Type B MS Program Meeting with FDA (3rd Quarter of 2025).
• Potential New Drug Application (NDA) submission for ALS under accelerated approval pathway (end of 2025), contingent on NfL findings.
• Discussion of planned Phase 3 study for MS focusing on cognition improvement.

Key Dates

Recommendation

Keywords

Clene, CLNN, FDA, ALS, Multiple Sclerosis, MS, Neurodegenerative Diseases, CNM-Au8, Biomarker, Neurofilament Light, NfL, New Drug Application, NDA, Accelerated Approval, Clinical Trial, Regulatory Update, Biopharmaceutical